16 July 2013

Ellex Spotlights SLT Technology at World Glaucoma Congress


The official launch of Ellex’s SLT technology into the US market will be marked at this year’s World Glaucoma Congress (WGC), taking place from 17-20 July in Vancouver, Canada. To highlight this milestone, Ellex will host an SLT Technology Summit on Thursday 18 July at the exclusive “Vancouver Club”.

The summit will bring together the industry’s leading SLT experts to discuss the latest developments in glaucoma management – and will also provide an opportunity for Ellex to provide some exciting updates on its SLT technology.

Keynote Speakers

Keynote speakers at the summit will be Cindy L. Hutnik, BSc, MD, PhD, FRCS(C) and Philip Y. Paden, MD. Dr. Hutnik is currently a Professor of Ophthalmology and Pathology at the Ivey Eye Institute in Ontario, Canada. With more than 10 years’ experience using SLT, she has performed over 2000 procedures and has come to view SLT as an effective alternative to medications.

“SLT works just as well as topical medications in lowering IOP and has an excellent safety profile. Most importantly, it is not plagued by the issues of compliance and side effects associated with medications,” says Dr Hutnik.

Dr. Paden, previously on the teaching faculty at the Cornell University Chemistry Department, is a board-certified ophthalmologist with almost three decades of experience. Since first adopting SLT in 2002 he has performed more than 2000 procedures and now offers it as a first-line therapy to the majority of his glaucoma patients. Dr. Paden agrees that SLT offers an effective alternative to medications which seldom yield the results expected due to issues of poor patient compliance.

“One of the main problems with anti-glaucoma medication is inconvenience, plain old forgetting – trying to remember to take an eye drop regardless of what is going on in one’s life, once a day, or several times a day. But patients also quit taking their medication because they don’t perceive a benefit, or due to the cost, or side effects,” says Dr. Paden.

“I give my patients the option to undergo SLT or commence treatment with anti-glaucoma eye drops. More than 98% elect SLT.”

WGC attendees interested in participating in the Ellex SLT Technology Summit should register their interest onsite at the Ellex Exhibit #112.

On display at the Ellex Exhibit #112 at WGC will be the Ellex Tango™ SLT/YAG combination laser system, Ellex’s flagship laser. Featuring a patented, proprietary dual-mode laser cavity, Tango™ is life-tested to deliver 400,000 shots with no loss of energy and also allows physicians to instantly switch between SLT and YAG modes at the touch of a button.


H A Quigley and A T Broman.The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 March; 90(3): 262–267.doi:  10.1136/bjo.2005.081224


Ellex Medical Lasers Limited (ASX:ELX) is a pioneer in the development of medical technologies for the diagnosis and treatment of eye disease. Since 1985, Ellex has evolved from a manufacturing company of primarily OEM products to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany, France and Australia, and a network of distribution partners in more than 100 countries. Today, more than 17,000 Ellex laser and imaging systems are used worldwide in the fight against blindness. In more recent times, Ellex has diversified its product range to include distribution of a number of complementary third-party ophthalmic products.